Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

Novavax

Pfizer

Vaxart

These Vaccine Latecomers Could Still Win Big. Here's How

The biotech's pan-COVID-19 vaccine caught the eye of investors last month.

Why Inovio Pharmaceuticals Stock Perked Up in May

A recent article wondered if the smart money preferred Ocugen or Inovio. I would hope neither INO stock or OCGN is getting any serious money.

I Would Hope Inovio Isn't Attracting ANY Serious Money

PLYMOUTH MEETING, Pa., June 3, 2021 /PRNewswire/ -- Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announced today positive preliminary results of its ongoing first-in-human trial.

Geneos Therapeutics Announces Clinical Updates on Personalized Cancer Vaccine Program

This troubled coronavirus vaccine developer has created far more woes than joys for investors.

Is It Too Late to Buy Inovio Pharmaceuticals Stock?

INOVIO Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Jefferies 2021 Virtual Healthcare Conference (Transcript)

Alpha Pro Tech

Gilead Sciences

iBio

QuidelOrtho Corp

Sorrento Therapeutics Inc

The pandemic bolstered many stocks to buy. But with cases fading, this narrative is now questionable.

7 Former Pandemic Stocks to Buy That Are No Longer Running Hot

PLYMOUTH MEETING, Pa., May 25, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO) a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, announced today that Dr. Joseph Kim, President and CEO, is scheduled to participate in a fireside chat and 1x1 investor meetings at the Jefferies 2021 Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:00 PM EDT.

INOVIO to Present at the Jefferies 2021 Virtual Healthcare Conference

Ocugen, Inc.

They're both seeking share in the vaccine market.

Ocugen vs. Inovio: Where Is the Smart Money Going?

Maybe not -- especially outside of the U.S.

Inovio's Latest COVID Vaccine Results: Too Little, Too Late?

This company could benefit from a near-term need -- and a long-term one, as well.

2 Things That May Boost This Beaten-Down Vaccine Stock

PLYMOUTH MEETING, Pa., May 17, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the appointment of Roger D.

INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors

1 Coronavirus Vaccine Company to Avoid Like The Plague in May (and Beyond)

Inovio Pharmaceuticals Inc (NASDAQ: INO) has announced results from a preclinical study of its next-generation Pan-COVID-19 vaccine candidate, INO-4802, that demonstrates its potential to induce cross-reactive immune responses against current and emerging viral variants. Data showed the vaccine candidate induced potent neutralizing antibodies and T cell responses against the original Wuhan strain as well as against B.1.1.7 (U.K. variant), B.1.351 (South African variant), and P.1.

Inovio's Pan-COVID-19 Vaccine Candidate Can Provide Immune Responses Against Variants, Animal Study Shows

PLYMOUTH MEETING, Pa., May 12, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that its next-generation Pan-COVID-19 vaccine candidate, INO-4802, induced potent neutralizing antibodies and T cell responses against the original Wuhan strain as well as against B.1.1.7 (UK variant), B.1.351 (South African variant) and P.1.

INOVIO's Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies

Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim on Q1 2021 Results - Earnings Call Transcript

PLYMOUTH MEETING, Pa., May 10, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results for the quarter ended March 31, 2021.

INOVIO Reports First Quarter 2021 Financial Results

The stock price of INOVIO (NASDAQ:INO) increased by over 3% pre-market. This is why it happened.

INO Stock: Over 3% Increase Pre-Market Explanation

Shares of Inovio Pharmaceuticals Inc. gained 8.0% in premarket trading on Monday after the company said its experimental COVID-19 vaccine was safe and also triggered antibody titers in 400 or so adult participants in a Phase 2 clinical trial. The results were published Friday as a preprint.

Inovio's stock is up after it shares new data from Phase 2 clinical trial for its COVID-19 vaccine candidate

PLYMOUTH MEETING, Pa., May 10, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced positive safety, tolerability and immunogenicity data from its placebo-controlled and blinded Phase 2 segment of its Phase 2/3 clinical trial in the U.S., called INNOVATE ( IN OVIO I NO -4800 Va ccine T rial for E fficacy), evaluating INO-4800, its DNA vaccine candidate for COVID-19.

INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine

Inovio's INO-4800 path forward remains ex-US. Expect an announcement on the FDA partial hold to be removed very soon. A spin-off opportunity is available and should be considered.

Inovio Pharmaceuticals: Once Bitten, Twice Shy

PLYMOUTH MEETING, Pa., May 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that INOVIO management will present at the following virtual investor conferences in May: Bank of America Merrill Lynch Health Care Conference Date: Tuesday, May 12, 2021 Time: 9:30 AM ET Presentation Format: Fireside Chat RBC Global Healthcare Conference Date: Tuesday, May 18, 2021 Time: 9:45 AM ET Presentation Format: Fireside Chat Live and archived versions of the virtual presentations will be available through the INOVIO Investor Relations Events page and may be accessed by visiting INOVIO's website at http://ir.inovio.com/investors/events/default.aspx.

INOVIO to Present at Upcoming Investor Conferences in May

Intercept Pharma

Sarepta Therapeutics

Analysts believe these underperformers could nearly double over the next 12 months.

3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street

The Department of Defense pulled its funding for Inovio Pharmaceuticals' final-phase Covid vaccine test in late April, leading INO stock to crumble. Is Inovio stock a sell today?

Is Inovio Stock A Sell After U.S. Officials Cut Funding For Covid Vaccine?

It might be able to, although it won't be easy.

News for Inovio Pharmaceuticals Stock (INO)